EMA publishes GVP Module V (Revision 2) for public comment
Recommendation

Thursday, 29 October 2026 9 .00 - 17.15 h
AI/ML-based Methods for Optimizing Pharmaceutical Research Processes
Eudralex Volume 9: The European Medicines Agency (EMA ) recently published GVP (Guideline on Good Pharmacovigilance Practices) Module V (Revision 2, major revision) for comment. The GVP-Module V covers the topic risk management. Aditionally the template for preparation of a Risk Management Plan (RMP) has been revised.
Deadline for comments for both documents is May 31, 2016.
The following Changes have been incorporated in the document:
- further clarification of what RMPs should focus on in relation to an important identified or important potential risk and missing information;
- removal of duplication within GVP Module V;
- removal of duplication of information in other guidance documents;
- further guidance on the expected changes in the RMP during the life cycle of the product;
- updated requirements for different types of initial marketing authorisation applications, with the aim to create risk-proportionate, fit for purpose RMPs.
Furthermore, the EMA addressed questions on which the agency seeks specific feedback by means of the public consultation:
- The updated risk definitions and guidance on Part II Module SVII of the RMP may lead, in the post-authorisation phase, to a list of safety concerns in the RMP that is a subset of the list of the product safety concerns as defined in the PSUR. What should be the priority of the GVP Module V: a focused RMP list of safety concerns or the full alignment with the PSUR content?
- Should studies conducted by the MAH but neither required nor imposed by the competent authority (previously classified as category 4 studies) be included, for information, in the RMP Annex 2?
- Should the additional risk minimisation materials as they were distributed in the Member States be included in the annexes of the RMP (i.e. RMP annex 6 – part B)?
- Should section V.B.10 be maintained or deleted (i.e. in the light of the RMP terminology described in V.A.1.)?
You can find the complete draft of Guideline on good pharmacovigilance practices: Module V – Risk-management systems on the Eudralex Vol. 9 website under Draft GVP chapters and annexes for public consultation, and the draft guidance on format of the risk management plan (RMP) in the EU – in integrated format on the EMA Risk-management plans website.
Related GMP News
11.06.2026In-use Storage Time of Reconstituted Medicines
11.06.2026Pilot on Real-Time Clinical Trials
28.05.2026New EMA Q&A on the Implementation of 3DP Technology
28.05.2026EMA publishes Presentations on Contractual Agreements in Clinical Trials
28.05.2026UK Substantial Modifications Pilot
07.05.2026What are the GMP Requirements for Investigational Medicinal Products (IMPs)?

